BioDelivery Sciences International Inc (BDSI)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:BioDelivery Sciences International Inc (BDSI) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8012258
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月14日
◆ページ数:49
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
BioDelivery Sciences International Inc (BDSI) is a specialty pharmaceutical company which develops and commercializes products in the areas of addiction medicine and pain management. The company’s marketed products include fentanyl buccal soluble solution for breakthrough cancer pain; buprenorphine/naloxone buccal film for opioid dependence; and buprenorphine buccal film for chronic pain. Its pipeline encompasses indications targeted at the treatment of chronic pain and opioid dependence. BDSI employs its proprietary BioErodible MucoAdhesive (BEMA) technology which comprises small, bioerodible polymer film used to facilitate rapid delivery a drug across the mucous membranes for time sensitive conditions. BDSI is headquartered in Raleigh, North Carolina, the US.

BioDelivery Sciences International Inc (BDSI) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
BioDelivery Sciences International Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
BioDelivery Sciences International Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
BioDelivery Sciences International Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
BioDelivery Sciences International Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
BioDelivery Sciences International Inc, Medical Devices Deals, 2011 to YTD 2017 10
BioDelivery Sciences International Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
BioDelivery Sciences International Inc, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
BioDelivery Sciences Enters into Co-Development Agreement with Evonik 12
Licensing Agreements 13
Purdue Pharma (Canada) Enters into Licensing Agreement with BioDelivery Sciences International 13
Collegium Pharma Enters into Licensing Agreement with BioDelivery Sciences International 14
BioDelivery Sciences Enters Into Licensing Agreement With Arcion For Topical Clonidine Gel 15
Equity Offering 17
BioDelivery Sciences Completes Private Placement Of Shares For US$60 Million 17
BioDelivery Sciences Completes Public Offering Of Common Stock And Prferred Stock For US$40 Million 18
BioDelivery Sciences International Completes Private Placement Of US$15 Million 20
BioDelivery Sciences International Inc – Key Competitors 21
BioDelivery Sciences International Inc – Key Employees 22
BioDelivery Sciences International Inc – Locations And Subsidiaries 23
Head Office 23
Other Locations & Subsidiaries 23
Recent Developments 24
Financial Announcements 24
Nov 09, 2017: BioDelivery Sciences Reports Third Quarter 2017 Financial Results and Provides Corporate Update 24
Aug 09, 2017: BioDelivery Sciences Reports Second Quarter 2017 Financial Results and Provides Corporate Update 26
May 15, 2017: BioDelivery Sciences Reports First Quarter 2017 Financial Results and Provides Corporate Update 28
Mar 17, 2017: BioDelivery Sciences Provides Corporate Update and Reports Fourth Quarter and Full-Year 2016 Financial Results 30
Nov 09, 2016: BioDelivery Sciences Provides Corporate Update and Reports Third Quarter 2016 Financial Results 33
Aug 09, 2016: BioDelivery Sciences Provides Corporate Update and Reports Second Quarter 2016 Financial Results 35
May 10, 2016: BioDelivery Sciences Provides Corporate Update and Reports First Quarter 2016 Financial Results 38
Mar 10, 2016: BioDelivery Sciences Provides Corporate Update and Reports Fourth Quarter and Full-Year 2015 Financial Results 40
Corporate Communications 42
Aug 23, 2017: BioDelivery Sciences President and Chief Executive Officer Dr. Mark A. Sirgo to Retire at Year-End While Continuing as Vice Chairman 42
Oct 05, 2016: BioDelivery Sciences Announces Additions to its Board of Directors 43
Product News 44
09/30/2016: BioDelivery Sciences Cites Impressive Number of Physicians Granted Waiver to Increase Patient Limit for Opioid Dependence Treatment Following Recent HHS Rule 44
03/04/2016: BioDelivery Sciences to provide an update on BELBUCA (buprenorphine) at the Cowen And Company 36th Annual Healthcare Conference and the 28th Annual Roth Conference 45
03/04/2016: BioDelivery Sciences to provide an update on Buprenorphine Injection at the Cowen And Company 36th Annual Healthcare Conference and the 28th Annual Roth Conference 46
02/22/2016: BioDelivery Sciences Announces the Launch of BELBUCA (Buprenorphine) Buccal Film by Endo Pharmaceuticals for Chronic Pain Management 47
Clinical Trials 48
Jun 03, 2016: New Data Demonstrate Safety Of Long-Term, Around-The-Clock Treatment With BELBUCA (Buprenorphine) Buccal Film For Chronic Pain 48
Appendix 49
Methodology 49
About GlobalData 49
Contact Us 49
Disclaimer 49

List of Tables
BioDelivery Sciences International Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
BioDelivery Sciences International Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
BioDelivery Sciences International Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
BioDelivery Sciences International Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
BioDelivery Sciences International Inc, Deals By Therapy Area, 2011 to YTD 2017 9
BioDelivery Sciences International Inc, Medical Devices Deals, 2011 to YTD 2017 10
BioDelivery Sciences International Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
BioDelivery Sciences Enters into Co-Development Agreement with Evonik 12
Purdue Pharma (Canada) Enters into Licensing Agreement with BioDelivery Sciences International 13
Collegium Pharma Enters into Licensing Agreement with BioDelivery Sciences International 14
BioDelivery Sciences Enters Into Licensing Agreement With Arcion For Topical Clonidine Gel 15
BioDelivery Sciences Completes Private Placement Of Shares For US$60 Million 17
BioDelivery Sciences Completes Public Offering Of Common Stock And Prferred Stock For US$40 Million 18
BioDelivery Sciences International Completes Private Placement Of US$15 Million 20
BioDelivery Sciences International Inc, Key Competitors 21
BioDelivery Sciences International Inc, Key Employees 22
BioDelivery Sciences International Inc, Subsidiaries 23

★海外企業調査レポート[BioDelivery Sciences International Inc (BDSI)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Promimic AB-医療機器分野:企業M&A・提携分析
    Summary Promimic AB (Promimic) is a biomaterial company that develops and markets implant surface modifications and synthetic bones. The company’s products comprise metals, ceramics, polymers, porous materials and pyrocarbon. Its HA-nano surface is a coating based on nanocrystalline hydroxyapatite p …
  • Orchids Paper Products Co:企業の戦略的SWOT分析
    Orchids Paper Products Co - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Neusoft Medical Systems Co Ltd-医療機器分野:企業M&A・提携分析
    Summary Neusoft Medical Systems Co Ltd (Neusoft Medical), a subsidiary of Neusoft Corp is a medical device company that provides medical equipment and services. The company offers medical imaging equipment, e-hospital solutions, regional medical and personal healthcare products. Its product portfoli …
  • MORRE-TEC Industries, Inc.:企業の戦略・SWOT・財務情報
    MORRE-TEC Industries, Inc. - Strategy, SWOT and Corporate Finance Report Summary MORRE-TEC Industries, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • AMEWAS, Inc.:企業の戦略・SWOT・財務情報
    AMEWAS, Inc. - Strategy, SWOT and Corporate Finance Report Summary AMEWAS, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Damco International B.V.:企業の戦略・SWOT・財務分析
    Damco International B.V. - Strategy, SWOT and Corporate Finance Report Summary Damco International B.V. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Eesti Energia AS-エネルギー分野:企業M&A・提携分析
    Summary Eesti Energia AS (Eesti Energia) is an international energy company that offers energy solutions ranging from electricity, heat and fuel production to sales, customer service and ancillary energy services among others. Eesti Energia sells electricity to the Baltic retail customers and the wh …
  • Zoo Digital Group plc (ZOO):企業の財務・戦略的SWOT分析
    Summary Zoo Digital Group Plc (ZOO) is a technology company that offers localization and media production services. The company offers services such as subtitling, captioning, dubbing and digital distribution. Its activities include providing a range of services to allow television and movie content …
  • Carna Biosciences Inc (4572):製薬・医療:M&Aディール及び事業提携情報
    Summary Carna Biosciences Inc (Carna) is a biotechnology company that discovers and develops drugs for the treatment of cancer and inflammatory diseases. The company offers products such as kinase proteins, biotinylated kinases, substrates, assay kits, protein substrates, inactive kinases, inactive- …
  • Aperam SA:企業の戦略・SWOT・財務情報
    Aperam SA - Strategy, SWOT and Corporate Finance Report Summary Aperam SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • Bristol-Myers Squibb Co (BMY):医療機器:M&Aディール及び事業提携情報
    Summary Bristol-Myers Squibb Co (BMS) is a specialty biopharmaceutical company that carries out the discovery, development, licensing, manufacturing, marketing, distribution and sale of medicines to patients with serious diseases. Its primary focus is on cancer, cardiovascular, immunology and virolo …
  • Superior Energy Services Inc (SPN):企業の財務・戦略的SWOT分析
    Superior Energy Services Inc (SPN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • University of Leicester-製薬・医療分野:企業M&A・提携分析
    Summary University of Leicester (UOL) is an educational service provider that offers undergraduate, postgraduate, distance learning and part-time programs. The university offers educational and research services in various disciplines such as mathematics, biochemistry, medicine, astrophysics, geneti …
  • Werner Enterprises, Inc.:企業の戦略・SWOT・財務情報
    Werner Enterprises, Inc. - Strategy, SWOT and Corporate Finance Report Summary Werner Enterprises, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Gordon Ramsay Holdings Limited:企業の戦略・SWOT・財務情報
    Gordon Ramsay Holdings Limited - Strategy, SWOT and Corporate Finance Report Summary Gordon Ramsay Holdings Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Electricity Authority of Cyprus:企業の戦略的SWOT分析
    Electricity Authority of Cyprus - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pro …
  • Microbix Biosystems Inc (MBX):企業の財務・戦略的SWOT分析
    Summary Microbix Biosystems Inc (Microbix) is a provider of biological and technology solutions for human health and wellbeing. The company's products include infectious disease antigens and quality assessment products. It manufactures viral and bacterial antigens and reagents for the diagnostics. M …
  • Hibu Group Limited:戦略・SWOT・企業財務分析
    Hibu Group Limited - Strategy, SWOT and Corporate Finance Report Summary Hibu Group Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Nishimatsu Construction Co., Ltd. (1820):企業の財務・戦略的SWOT分析
    Nishimatsu Construction Co., Ltd. (1820) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • Legg Mason Inc:企業の戦略・SWOT・財務情報
    Legg Mason Inc - Strategy, SWOT and Corporate Finance Report Summary Legg Mason Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆